Phase 3 results for Cx601 in treatment of complex perianal fistulas in patients with Crohn's disease

Takeda Pharmaceutical Company Limited and TiGenix NV have announced that the 24week results of the Phase 3 ADMIRECD trial investigating Cx601 have been published in The Lancet . Cx601 is a suspension of allogeneic adiposederived stem cells injected intrale...